The EuroSCORE has been proposed to identify patients at high risk for surgical aortic valve replacement (AVR) and estimate for them the risk-benefit of percutaneous valve replacement. The aim of our study was to investigate the validity of this proposal.
Introduction
It remains common for patients to present for valve replacement at an advanced stage of aortic valve stenosis. 1 This may be explained in part by current guidelines in western countries that support rather late surgical intervention. 2, 3 The result is a substantial number of patients who do not come for the operation for a variety of reasons, such as old age and multiple morbidities, but who may benefit from a lower-risk percutaneous valve replacement. Appropriately, in clinical trials during this early developmental phase of percutaneous aortic valve replacement (AVR), patients at high risk for surgical AVR are being recruited. Various existing tools devised in part for stratifying patients according to expected surgical risk 4 -6 could be proposed to identify these high-risk patients and to estimate the degree to which a percutaneous approach may lower that risk. It may not be appreciated that risk stratification and risk prediction are separable issues: one addresses the relative risk and the other the absolute risk. Thus, a tool that retains a strong monotonic and distinctive association with mortality may perform well in settings requiring relative risk stratification, but poorly in other settings requiring accurate absolute risk estimates.
Recently, one such tool, the EuroSCORE, has been used to select high-risk patients for percutaneous AVR and to compare survival after these procedures with that predicted had surgical AVR been performed. 7, 8 However, the EuroSCORE is based on 1995 mortality across all of cardiac surgery, a time at which coronary artery bypass grafting dominated the patient population, not heart valve disease. Therefore, aims of this study were to discover (i) whether the EuroSCORE accurately predicts absolute 30-day mortality after contemporary AVR, (ii) whether it accurately stratifies such patients according to risk, and (iii) whether its utility for risk prediction and stratification has diminished across time.
Methods
Patients Table 1 . This patient population was conceived as the one most closely approximating the aortic valve pathology of candidates for percutaneous AVR.
Data acquisition and follow-up
All data were collected prospectively by healthcare providers concurrent with patient care during the hospitalization using the Heidelberg Association for multi-centric data analysis. This database includes about 1500 standardized variables per patient. It is used for direct patient management (reports), reimbursement, internal and external quality assurance programs, and research. The transparency and multifunctional use of the data provide multiple data checks, achieving a high level of reliability. 9 Routine patient follow-up was performed 180 days after AVR, with data available for evaluating 30-day hospital mortality in 99.8% of patients. We used 30-day hospital mortality because it is the focus of the EuroSCORE and percutaneous AVR assessment. Even before publication of the EuroSCORE in 1999, equivalent variables existed in our database, defined in the same fashion.
Definition of risk groups
Low-, medium-, and high-risk subgroups were identified according to the published risk-stratification definition. 5 An additive EuroSCORE of 0 -2 or logistic EuroSCORE calculated probability of ,3% defined low-risk patients; an additive score of 3 -5 or logistic probability of 3%-,6% defined medium-risk patients; and an additive score of 6 or logistic probability of 6% defined high-risk patients. The high-risk group was further subdivided for some analyses between those with scores ,12 and 12 or greater. Grube et al. 7 considered a patient to represent a high risk patient if there was a consensus among an independent cardiologist and cardiac surgeon that conventional surgery would be associated with excessive morbidity and mortality. 
Data analysis
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Both additive and logistic EuroSCOREs were calculated for each patient and summarized by adding these scores within risk strata to yield expected number of events, expressed as a percentage. Numbers of expected vs. observed deaths were compared by calculating a chi-square goodness-of-fit statistics. Sensitivity and specificity of expected vs. observed mortality were summarized by receiveroperator curves and the area under the resulting curve (AUC), expressed as a C-statistic. A decreasing value of this statistic from 1.0 toward 0.5 indicates decreasing distinctiveness or discrimination between patients living and dead. At any level of distinctiveness, risk stratification may remain monotonic (i.e. expected mortality increases progressively in concert with observed mortality). We quantitatively determined whether the EuroSCORE retained its relative risk association with 30-day mortality. For this, we incorporated the EuroSCORE into a logistic regression model and compared the beta coefficient (slope) with the expected value of 1.0, which would indicate 100% retention of relative risk. A slope of ,1.0 indicates a decreased strength of association with EuroSCORE. A smaller logistic regression intercept with a slope of 1.0 indicates preserved strength of association, but lower overall risk of AVR at all levels of EuroSCORE.
We also examined whether across eras, the EuroSCORE became increasingly uncalibrated with respect to risk. For this, a separate logistic regression analysis was performed for three eras: 1994 -1977, 1998 -2001, and 2002-2006. For calibration plots, observed vs. expected mortality was depicted from the model in 10 equal-sized groups, based on deciles of predicted mortality with calibration assessed by the Hosmer -Lemeshow statistic. For all calculations, SAS version 9.1 (SAS, Inc., Cary, NC, USA) was used.
Presentation
Continuous variables are summarized by mean + standard deviation and median, and categorical variables by frequency and percentage. Mortality is accompanied by 95% CI.
Results
Observed vs. predicted 30-day mortality 
Discussion Risk estimation by the EuroSCORE
According to the general observation and the present study, advances in surgical and perioperative treatment have steadily reduced procedural risk of AVR to low levels, even in high-risk patients. A major shift in patient characteristics towards a higher proportion of so-called high-risk patients began in the 1980s and 1990s and still continues to some extent, 10 although this trend was not apparent in our 1994-2006 study group. Failure of both EuroSCOREs to predict mortality accurately in high-risk patients in a mixed cardiac surgical patient cohort has already been described. 11 For patients with isolated aortic valve disease in the current era, overestimation of risk of AVR is substantial. The revised version of another widely used score in cardiac surgery, the Parsonnet score, 12 is rarely applied and possibly has the same weaknesses as other scores in part because neutralization of risk factors is an ongoing process 13 and in part because it is not disease specific. Other scoring systems, such as the STS models, are different for each patient subgroup and may be more accurate in predicting risk for primary isolated AVR. We did not investigate this possibility because in contrast to the Euro-SCORE, which is publicly available, the STS models are proprietary and have never been released in a usable form as required by accepted guidelines for risk-scoring systems.
14 Potential reasons for the low predictive capacity of the Euro-SCORE for patients with isolated AVR can be summarized as follows:
(i) The present EuroSCORE was devised using a mixed patient population undergoing cardiac surgery, but the majority were treated for coronary artery disease, and only a minority for primary isolated AVR. (ii) The EuroSCORE is based on data from 1995 and has not as yet been updated or recalibrated, although efforts are under way to do so. Thus, predicted mortality after primary isolated AVR is underestimated and has progressively become less well calibrated to absolute risk across time since its development. Nevertheless, it still accurately stratifies risk because it retains a strong association with mortality. (iii) The EuroSCORE as a risk-adjustment mechanism accounts for only the most common and prevalent risk factors for 30-day mortality. Unusual combinations of risk factors and rare ones not accounted for in the score tend to place patients at extremes of risk. These patients with unaccounted-for factors are expected to experience greater mortality than predicted. 15 Surprisingly, underestimation of risk was not observed in our study. This, then, does not help explain our observations.
(iv) The relatively low mortality observed in the highest risk subgroup of our patients may be a chance finding due to small numbers.
No matter which of these potential reasons resulted in low predictive capacity of both EuroSCOREs, what is clear is that neither accurately predicts risk for an individual patient. This fact must be taken into account if one aim of using the EuroSCORE is to estimate risk reduction from use of percutaneous vs. surgical AVR.
Potential interpretation of the results
Because of neutralization of risk factors, patients undergoing surgical AVR in the current era have a low procedural risk. 13 The substantial reduction of mortality observed throughout the total patient group, especially in the last decade, indicates that the 'Carthagesian dream' 16 of minimizing human error through standardization and medical progress seems to be becoming a reality. Low procedural risk even in so-called high-risk patients should invite reconsideration of current guidelines for patients with aortic valve stenosis, which recommend restricting valve replacement for advanced symptomatic stages of disease.
1,2 However, patients with pronounced symptoms from longstanding disease not only have advanced valvular alterations, such as cusp and anulus calcifications, but also ventricular remodelling, including hypertrophy, irreversible ultrastructural myocardial damage of left ventricular myocardium, 17 and some degree of left ventricular outflow tract obstruction that often requires subvalvular myectomy to minimize the gradient between left ventricle and ascending aorta. 18 So, in contrast to the guidelines, in even low-risk patients with less extensive cardiac and non-cardiac comorbidity, an earlier surgical valve replacement is necessary to obtain optimal treatment at low risk and to preserve myocardial integrity.
19,20
EuroSCORE for decision-making in percutaneous valve replacement 22 and ventricular net devices. 23 Limitations of the study
The study was performed with data of a single University Hospital. A pre-selection of patients had been performed at least intuitively by cardiologists. The potential impact of patient selection in terms of a selection bias leading to a non-representative study population may be similar to the results of the Euro Heart Survey on Coronary Revascularization. 24 However, likely a large number of patients are not referred for surgery. All patients referred for primary isolated AVR were accepted for surgery independent of their risk profile. The proportion of high-risk patients supports liberal patient selection. At n ¼ 71, however, the number of very high-risk patients is small.
Conclusions
The additive and logistic EuroSCOREs remain useful for relative risk stratification. Because of this, they may remain valuable for identifying the highest-risk patients for percutaneous AVR. However, advances in safety of cardiac surgery since their construction have led to inaccuracy in predicting absolute risk. Thus, when these scores are used to estimate reduction in expected surgical risk by percutaneous AVR, the magnitude of the reduction is likely exaggerated and may even be in the wrong direction (higher risk than conventional surgery). A more accurate tool than the current EuroSCOREs, possibly AVR specific, is needed to assist in selecting appropriate patients for percutaneous AVR and assessing early results.
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